Insider · CIK 0001266062

BROWN MORGAN R

Reports to the SEC for 5 companies · SALT LAKE CITY, UT

sec.gov

Transactions

Companies

Filings

CIK

0001266062

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-11	CLNNClene Inc. · stock optionA Award	Chief Financial Officer	AAward	+15K sh	—	—	15,000
2026-01-22	CLNNClene Inc. · stock optionA Award	Chief Financial Officer	AAward	+35K sh	—	—	35,000
2025-09-25	CLNNClene Inc. · stock optionA Award	Chief Financial Officer	AAward	+10K sh	—	—	10,000
2025-09-18	CLNNClene Inc. · stock optionA Award	Chief Financial Officer	AAward	+10K sh	—	—	10,000
2025-02-24	CLNNClene Inc. · Stock Options (Right to buy)A Award	Chief Financial Officer	AAward	+20K sh	—	—	20,000
2024-08-16	CLNNClene Inc. · Stock Options (Right to buy)A Award	Chief Financial Officer	AAward	+10K sh	—	—	10,000
2024-06-07	CLNNClene Inc. · Stock Options (Right to buy)A Award	Chief Financial Officer	AAward	+400K sh	—	—	400,000
2024-06-07	CLNNClene Inc. · Stock Options (Right to buy)A Award	Chief Financial Officer	AAward	+600K sh	—	—	600,000
2023-06-29	CLNNClene Inc. · Stock Options (Right to buy)A Award	Chief Financial Officer	AAward	+400K sh	—	—	400,000
2023-02-17	CLNNClene Inc. · Stock Options (Right to buy)A Award	Chief Financial Officer	AAward	+125K sh	—	—	125,000
2022-11-04	CLNNClene Inc. · Stock Options (Right to buy)A Award	Chief Financial Officer	AAward	+300K sh	—	—	300,000
2022-02-01	CLNNClene Inc. · Stock Options (Right to buy)A Award	Chief Financial Officer	AAward	+250K sh	—	—	250,000
2021-12-07	LPCNLipocine Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+176K sh	$1.12	+$197K	176,000
2020-12-16	LPCNLipocine Inc.S Sale	Chief Financial Officer	SSale	−8,437 sh	$1.35	−$11.4K	194,504
2020-12-16	LPCNLipocine Inc. · Restricted Stock UnitM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+28.1K sh	—	—	28,125
2020-12-16	LPCNLipocine Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+28.1K sh	—	—	202,941
2020-12-15	LPCNLipocine Inc. · Stock Options (Right to Buy)A Award	Chief Financial Officer	AAward	+160K sh	$1.37	+$219K	160,000
2020-12-05	LPCNLipocine Inc. · Restricted Stock UnitM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−70.8K sh	—	—	70,754
2020-12-05	LPCNLipocine Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+70.8K sh	—	—	174,816
2020-12-04	LPCNLipocine Inc.S Sale	Chief Financial Officer	SSale	−17.3K sh	$1.57	−$27K	104,062
2020-12-04	LPCNLipocine Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+57.5K sh	—	—	121,312
2020-12-04	LPCNLipocine Inc. · Restricted Stock UnitM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−57.5K sh	—	—	57,500
2020-01-28	LPCNLipocine Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+132K sh	$0.46	+$60.5K	132,000
2019-12-05	LPCNLipocine Inc. · Restricted Stock UnitA Award	Chief Financial Officer	AAward	+70.8K sh	—	—	70,754
2019-12-04	LPCNLipocine Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+57.5K sh	—	—	81,062
2019-12-04	LPCNLipocine Inc.S Sale	Chief Financial Officer	SSale	−17.3K sh	$0.41	−$7,075.95	63,812
2019-12-04	LPCNLipocine Inc. · Restricted Stock UnitM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−57.5K sh	—	—	57,500
2018-12-04	LPCNLipocine Inc. · Restricted Stock UnitA Award	Chief Financial Officer	AAward	+115K sh	—	—	115,000
2018-12-04	LPCNLipocine Inc. · Stock Option (Right to buy)A Award	Chief Financial Officer	AAward	+75K sh	$1.46	+$110K	75,000
2017-12-29	LPCNLipocine Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+9,375 sh	—	—	26,375
2017-12-29	LPCNLipocine Inc. · Restricted Stock UnitM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−9,375 sh	—	—	28,125
2017-12-29	LPCNLipocine Inc.S Sale	Chief Financial Officer	SSale	−2,813 sh	$3.47	−$9,773.487	23,562
2017-12-06	LPCNLipocine Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+75K sh	$3.52	+$264K	75,000
2017-01-26	LPCNLipocine Inc. · Restricted Stock UnitA Award	Chief Financial Officer	AAward	+37.5K sh	—	—	37,500
2016-12-07	LPCNLipocine Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+50K sh	$3.61	+$181K	50,000
2016-01-05	LPCNLipocine Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+50K sh	$12.92	+$646K	50,000
2014-08-14	LPCNLipocine Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+34.3K sh	—	—	34,268
2013-12-10	LPCNLipocine Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+15K sh	—	—	15,000
2013-12-10	LPCNLipocine Inc. · Restricted Stock UnitA Award	Chief Financial Officer	AAward	+5,000 sh	—	—	5,000
2013-09-16	LPCNLipocine Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+50K sh	—	—	50,000
2013-09-16	LPCNLipocine Inc.A Award	Chief Financial Officer	AAward	+12K sh	—	—	12,000
2013-05-28	INNOVUS PHARMACEUTICALS, INC.A Award	See remarks	AAward	+750K sh	—	—	750,000
2013-05-28	INNOVUS PHARMACEUTICALS, INC.A Award	See remarks	AAward	+750K sh	—	—	750,000
2011-09-01	WORLD HEART CORPStock Option (Rt to buy)A Award	Executive VP	AAward	+8,800 sh	$0.44	+$3,872	8,800
2011-06-30	WORLD HEART CORPStock option (Rt to buy)A Award	Executive VP	AAward	+51K sh	$0.99	+$50.5K	51,000
2011-02-10	WORLD HEART CORPStock option (Rt to buy)A Award	Executive VP	AAward	+25K sh	$1.65	+$41.3K	25,000
2010-02-04	WORLD HEART CORPStock Option (Rt to Buy)A Award	Executive VP	AAward	+22K sh	—	—	22,000
2009-08-10	WORLD HEART CORPStock Option (Rt to Buy)A Award	Executive VP	AAward	+110K sh	—	—	110,000
2006-01-17	NPS PHARMACEUTICALS INCStock OptionA Award	Vice President, Finance	AAward	+5,925 sh	—	—	5,925
2005-07-15	NPS PHARMACEUTICALS INCStock OptionA Award	Vice President, Finance	AAward	+5,925 sh	—	—	5,925

Recent filings

Accepted (ET)
Jun 154
BROWN MORGAN R0001437749-26-020635
SEC(opens sec.gov)
Jan 234
BROWN MORGAN R0001437749-26-001915
SEC(opens sec.gov)
Sep 294
BROWN MORGAN R0001437749-25-030014
SEC(opens sec.gov)
Sep 194
BROWN MORGAN R0001437749-25-029477
SEC(opens sec.gov)
Feb 254
BROWN MORGAN R0001562180-25-001590
SEC(opens sec.gov)
Aug 194
BROWN MORGAN R0001562180-24-006353
SEC(opens sec.gov)
Jun 114
BROWN MORGAN R0001562180-24-004945
SEC(opens sec.gov)
Jul 34
BROWN MORGAN R0001562180-23-005630
SEC(opens sec.gov)
Feb 214
BROWN MORGAN R0001562180-23-001571
SEC(opens sec.gov)
Nov 74
BROWN MORGAN R0001562180-22-007531
SEC(opens sec.gov)
Feb 34
BROWN MORGAN R0001562180-22-001004
SEC(opens sec.gov)
Dec 84
BROWN MORGAN R0001493152-21-030817
SEC(opens sec.gov)
Dec 174
BROWN MORGAN R0001638599-20-000976
SEC(opens sec.gov)
Dec 84
BROWN MORGAN R0001638599-20-000948
SEC(opens sec.gov)

Companies

Address

6550 SOUTH MILLROCK DRIVE SUITE G50

SALT LAKE CITY, UT, 84121